[The best in 2000 on heart failure].
The advances in cardiac failure are permanent. In 2000, once again, they concerned all fields of pathology. Complementary information of the epidemiology of the disease in France and Europe has been published. The prevention of sudden death by the implantable defibrillator in hypertrophic cardiomyopathy has been confirmed. The prognostic role of the aetiology of dilated cardiomyopathy has been demonstrated and the distinct clinical entity of acute fulminating viral myocarditis with an excellent long-term prognosis has been identified. New genetic abnormalities have been found in different forms of dilated cardiomyopathy. One of the most important advances concerns the neurohormones and the rise of interest in type B natriuretic peptide, for diagnosis, prognosis, as well as treatment (nesiritide). From the therapeutic point of view, the importance of betablockers has been confirmed, including in severe cardiac failure. The therapeutic value of biventricular stimulation resynchronising the two ventricles seem to be an additional therapeutic opportunity for patients with advanced cardiac failure. The summit of 2000 remains the first cellular transplantation carried out by a Parisian French team.
Juillière
Y
Y
Service de cardiologie, CHU Nancy-Brabois, Allée du Morvan, 54500 Vandoeuvre-lès-Nancy.
D009202:Cardiomyopathies / Q000150:complications; D017690:Cell Transplantation; D006333:Heart Failure / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000628:therapy; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000502:physiology
D020097:Natriuretic Peptide, Brain